Spark Therapeutics, Inc. (NASDAQ:ONCE) insider Daniel Faga sold 6,000 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $82.50, for a total value of $495,000.00. Following the transaction, the insider now owns 6,000 shares of the company’s stock, valued at approximately $495,000. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Daniel Faga also recently made the following trade(s):

  • On Thursday, September 7th, Daniel Faga sold 3,000 shares of Spark Therapeutics stock. The stock was sold at an average price of $85.02, for a total value of $255,060.00.
  • On Monday, July 24th, Daniel Faga sold 3,000 shares of Spark Therapeutics stock. The stock was sold at an average price of $70.00, for a total value of $210,000.00.
  • On Thursday, June 29th, Daniel Faga sold 4,500 shares of Spark Therapeutics stock. The stock was sold at an average price of $62.71, for a total value of $282,195.00.

Spark Therapeutics, Inc. (ONCE) traded down 0.54% during mid-day trading on Thursday, hitting $81.27. The company’s stock had a trading volume of 345,144 shares. Spark Therapeutics, Inc. has a 52-week low of $35.07 and a 52-week high of $85.26. The company’s 50 day moving average is $82.11 and its 200-day moving average is $71.89. The stock’s market cap is $2.54 billion.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.75) by ($0.14). Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.33 million. During the same period in the prior year, the firm posted ($1.04) EPS. The business’s revenue for the quarter was up 14.7% on a year-over-year basis. On average, equities analysts predict that Spark Therapeutics, Inc. will post ($7.69) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Spark Therapeutics, Inc. (ONCE) Insider Sells 6,000 Shares of Stock” was published by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/09/14/insider-selling-spark-therapeutics-inc-once-insider-sells-6000-shares-of-stock.html.

Large investors have recently added to or reduced their stakes in the business. FMR LLC grew its holdings in Spark Therapeutics by 0.9% during the first quarter. FMR LLC now owns 4,656,655 shares of the biotechnology company’s stock valued at $248,386,000 after purchasing an additional 40,698 shares during the period. Teachers Advisors LLC grew its holdings in Spark Therapeutics by 16.8% during the fourth quarter. Teachers Advisors LLC now owns 33,884 shares of the biotechnology company’s stock valued at $1,691,000 after purchasing an additional 4,875 shares during the period. Bank of New York Mellon Corp grew its holdings in Spark Therapeutics by 10.9% during the first quarter. Bank of New York Mellon Corp now owns 111,043 shares of the biotechnology company’s stock valued at $5,923,000 after purchasing an additional 10,916 shares during the period. Nationwide Fund Advisors grew its holdings in Spark Therapeutics by 2.5% during the first quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock valued at $923,000 after purchasing an additional 414 shares during the period. Finally, American International Group Inc. grew its holdings in Spark Therapeutics by 17.4% during the first quarter. American International Group Inc. now owns 11,582 shares of the biotechnology company’s stock valued at $618,000 after purchasing an additional 1,714 shares during the period. 91.01% of the stock is owned by institutional investors and hedge funds.

Several research analysts have recently weighed in on ONCE shares. ValuEngine downgraded Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 20th. BidaskClub upgraded Spark Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. William Blair began coverage on Spark Therapeutics in a research note on Wednesday, June 28th. They issued an “outperform” rating for the company. Jefferies Group LLC began coverage on Spark Therapeutics in a research note on Monday, July 10th. They issued a “buy” rating and a $85.00 target price for the company. Finally, Zacks Investment Research downgraded Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $83.77.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.